UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 or 15(d) of the
SECURITIES EXCHANGE ACT OF 1934
Date of Report
April 19, 2006
(Date of earliest event reported)
IVAX Diagnostics, Inc.
(Exact name of registrant as specified in its charter)
| | | | |
| Delaware | | 1-14798 | | 11-3500746 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
| | |
2140 North Miami Avenue Miami, Florida | | 33127 |
| (Address of principal executive offices) | | (Zip Code) |
(305) 324-2300
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
On April 19, 2006, Dr. Phillip Frost, Mr. Neil Flanzraich, and Dr. Jane Hsiao resigned from IVAX Diagnostics, Inc.’s Board of Directors (the “Board”), and Dr. Itzhak Krinsky, Mark Durand and Richard Egosi were appointed to the Board to fill the vacancies and to serve until the next annual meeting of stockholders.
Dr. Krinsky, who is the Corporate Vice President – Business Development of Teva Pharmaceutical Industries Limited, has succeeded Dr. Frost as the non-executive Chairman of the Board. Mr. Durand is the Chief Financial Officer and Senior Vice President—Finance and Business Development for Teva North America. Mr. Egosi is the Senior Vice President and General Counsel for Teva North America.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | |
| IVAX DIAGNOSTICS, INC. |
| |
| By: | | /s/ Giorgio D’Urso |
| | Giorgio D’Urso, |
| | Chief Executive Officer and President |
Dated: April 20, 2006
